Trialsglp-1secukinumabnovartispsoriasis

Novartis registers real-world study of secukinumab retention with GLP-1 co-therapy

The non-interventional analysis tests whether 12-month secukinumab retention in psoriasis patients also taking a GLP-1 agonist is non-inferior to monotherapy.

By Priya Raman · Science Reporter

Oct 20 08:00 ETSource: ClinicalTrials.gov

The wire

01NCT07881783, sponsored by Novartis, is not yet recruiting and is scheduled to start 30 October 2026 in adults with moderate-to-severe plaque psoriasis.
02Primary aim is 12-month treatment retention with secukinumab plus a GLP-1 receptor agonist versus secukinumab alone, with adherence and healthcare resource use as secondary measures.
03It is a real-world data analysis rather than a randomized trial, so confounding by indication and patient weight status will limit interpretation.

From the source

A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
NCT07881783 · N/A · NOT YET RECRUITING · Sponsor: Novartis Pharmaceuticals · Conditions: Plaque Psoriasis.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT07881783